Presbyopia Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Santen Pharma, Glaukos Corporation, Ocuphire Pharma, Visus Therapeutics, LENZ

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Presbyopia pipeline constitutes 6+ key companies continuously working towards developing 6+ Presbyopia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Presbyopia Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Presbyopia Market.

The Presbyopia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Presbyopia Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Presbyopia treatment therapies with a considerable amount of success over the years.

*
Presbyopia companies working in the treatment market are Cellix Bio, Plex Pharmaceuticals, Santen Pharmaceutical, Glaukos Corporation, Ocuphire Pharma, Visus Therapeutics, LENZ Therapeutics, Eyenovia, Orasis Pharmaceuticals, Ocuphire Pharma, AbbVie, and others, are developing therapies for the Presbyopia treatment

*
Emerging Presbyopia therapies in the different phases of clinical trials are- CLX-OPH-162, Research programme, STN 1013600, GLK-302, Nyxol, VTI-001, LNZ100, MicroLine (Pilocarpine Ophthalmic), CSF-1 (PresbiDrops), Nyxol, VT-101 (Brimochol), AGN-241622, and others are expected to have a significant impact on the Presbyopia market in the coming years.

*
In October 2025, LENZ Therapeutics announced the U.S. availability of VIZZ, the first and only FDA-approved aceclidine-based eye drop for treating presbyopia in adults. Nationwide sample distribution to eye care professionals has begun, with commercial shipments to consumers set to start in October. This launch establishes LENZ as a significant player in the sizable and previously underserved U.S. presbyopia market, with clinical trials demonstrating rapid and lasting near-vision improvement for most patients.

*
In April 2025, Tenpoint Therapeutics, Ltd. ("Tenpoint"), a global clinical-stage biotech company dedicated to pioneering therapies that restore vision in aging eyes, has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for BRIMOCHOL Trademark PF. The drug is intended for the treatment of presbyopia, an age-related condition that causes near-vision loss and affects around two billion people worldwide, including 128 million in the United States.

*
In January 2025, Tenpoint Therapeutics, Inc., a global clinical-stage biotechnology company focused on innovative therapies to restore vision in aging eyes, announced encouraging topline results from its second Phase 3 pivotal trial, BRIO-II. The trial successfully met the pre-determined primary endpoints established in collaboration with the U.S. FDA, European Medicines Agency (EMA), and the UK's Medicines and Healthcare products Regulatory Agency (MHRA). BRIO-II showed statistically significant improvements in near vision compared to the vehicle across all measured timepoints, up to 8 hours post-treatment (p



This release was published on openPR.